IDH mutations and (R)-2-HG production are also known to antagonize prolyl-hydroxylases, which are regulators of HIF-1α [13, 17], promote cell growth [18], alter cell morphology [19], increase metastatic potential [19], and are associated with overall longer survival in glioma patients [4]. Here, IDH2 is linked to central nervous system cancer.